Supernus Pharmaceuticals Shares Outstanding 2012-2026 | SUPN

Supernus Pharmaceuticals shares outstanding from 2012 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Supernus Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2025 56
2024 56
2023 56
2022 62
2021 54
2020 54
2019 54
2018 54
2017 53
2016 52
2015 51
2014 42
2013 32
2012 17
2011 2
Supernus Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2026-03-31 58
2025-12-31 57
2025-09-30 57
2025-06-30 57
2025-03-31 56
2024-12-31 56
2024-09-30 56
2024-06-30 56
2024-03-31 56
2023-12-31 56
2023-09-30 55
2023-06-30 55
2023-03-31 62
2022-12-31 62
2022-09-30 55
2022-06-30 61
2022-03-31 61
2021-12-31 54
2021-09-30 54
2021-06-30 55
2021-03-31 54
2020-12-31 54
2020-09-30 54
2020-06-30 54
2020-03-31 54
2019-12-31 54
2019-09-30 54
2019-06-30 54
2019-03-31 54
2018-12-31 54
2018-09-30 54
2018-06-30 54
2018-03-31 54
2017-12-31 53
2017-09-30 54
2017-06-30 53
2017-03-31 53
2016-12-31 52
2016-09-30 52
2016-06-30 52
2016-03-31 51
2015-12-31 51
2015-09-30 52
2015-06-30 52
2015-03-31 45
2014-12-31 42
2014-09-30 43
2014-06-30 42
2014-03-31 41
2013-12-31 32
2013-09-30 31
2013-06-30 31
2013-03-31 31
2012-12-31 17
2012-09-30 24
2012-06-30 17
2012-03-31 2
2011-12-31 2
2011-09-30 2
2011-06-30 2
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.918B $0.719B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00